Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

246.09USD
27 Jun 2017
Change (% chg)

$-2.82 (-1.13%)
Prev Close
$248.91
Open
$247.71
Day's High
$249.91
Day's Low
$246.09
Volume
409,769
Avg. Vol
703,470
52-wk High
$261.27
52-wk Low
$184.58

AGN.N

Chart for AGN.N

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $82,653.52
Shares Outstanding(Mil.): 335.87
Dividend: 0.70
Yield (%): 1.14

Financials

  AGN.N Industry Sector
P/E (TTM): -- 13.69 17.46
EPS (TTM): -10.56 -- --
ROI: -2.81 -6.93 -5.20
ROE: -5.17 -6.40 -4.44

BRIEF-Allergan announces launch of artificial tear refresh optive mega-3

* Allergan plc - announced launch of over-the-counter artificial tear refresh optive mega-3 Source text for Eikon: Further company coverage:

27 Jun 2017

UPDATE 1-Mylan defends chairman to ISS ahead of June 22 investor vote

June 7 Mylan NV defended Chairman Robert Coury's role to ISS this week as the influential proxy firm prepares to advise shareholders on how they should vote on the re-election of Coury and other directors, according to a letter the drugmaker released on Wednesday.

07 Jun 2017

Mylan defends chairman to ISS ahead of June 22 investor vote

June 7 Mylan NV defended Chairman Robert Coury's role to ISS this week as the influential proxy firm prepares to advise shareholders on how they should vote on the re-election of Coury and other directors, according to a letter the drugmaker released on Wednesday.

07 Jun 2017

BRIEF-Amgen, Allergan announce FDA advisory committee meeting to review ABP 215

* Amgen and Allergan announce fda advisory committee meeting to review ABP 215, a biosimilar candidate to bevacizumab

07 Jun 2017

BRIEF-Allergan to acquire Keller Medical, adding Keller Funnel to co's leading plastic surgery portfolio

* Allergan to acquire Keller Medical, Inc., adding Keller Funnel® to company's leading plastic surgery portfolio Source text for Eikon: Further company coverage:

07 Jun 2017

BRIEF-Allergan announces closing of public offering

* Allergan announces closing of public offering of senior notes to refinance existing debt Source text for Eikon: Further company coverage:

26 May 2017

BRIEF-Allergan prices public offering of senior notes to refinance existing debt

* Allergan announces pricing of public offering of senior notes to refinance existing debt

24 May 2017

BRIEF-Allergan says VIBERZI now approved in Canada

* viberzi™ now approved in canada for patients with irritable bowel syndrome with diarrhea (ibs-d)

16 May 2017

Several top fund managers trim Allergan stakes in first quarter

NEW YORK Six closely watched investors sliced their stakes in Allergan Plc during the first quarter, recent regulatory disclosures show, cutting what had been one of the years' best performing health stocks that has stumbled in recent days.

16 May 2017

Several top fund managers trim Allergan stakes in 1st quarter

NEW YORK, May 15 Six closely watched investors sliced their stakes in Allergan Plc during the first quarter, recent regulatory disclosures show, cutting what had been one of the years' best performing health stocks that has stumbled in recent days.

16 May 2017

More From Around the Web

Earnings vs. Estimates